Atorvastatin: A Review of its Use in the Primary Prevention of Cardiovascula…

Atorvastatin (Lipitor®) is an HMG-CoA reductase inhibitor with well documented lipid-lowering effects. It has recently been evaluated for the primary prevention of major cardiovascular events in patients with type 2 diabetes mellitus without elevated serum low-density lipoprotein (LDL)-cholesterol levels.

Effect of Very High-Intensity Statin Therapy on Regression of Coronary Athero…

Prospective, open-label blinded end-points trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden [ASTEROID]) was performed at 53 community and tertiary care centers in the United States, Canada, Europe, and Australia. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. Ea…

Atorvastatin (Calcium)

Atorvastatin is a synthetic competitive inhibitor of 3-hydroxy-3-methlyglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step incholesterol biosynthesis

Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary …

BLOOD CHOLESTEROL LOWERing with statins has been regarded as a long-term strategy to reduce death and ischemic cardiovascular events in patients with stable coronary heart disease, with significant effects evident after approximately 2 years of treatment

The polymorphism of statins and its effect on their physicochemical properties

Polymorphism of pharmaceutical substances has a significant impact on their physicochemical properties, durability, bioavailability and consequently on their pharmacological activity. Solid dosage forms may exist in both crystalline and amorphous forms. Amorphous varieties are characterized by higher solubility and dissolution rates, while crystalline forms show greater purity and storage stab…

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Quantifying effect of statins on low density lipoprotein cholesterol, ischaem…

To determine by how much statins reduce serum concentrations of low density lipoprotein (LDL) cholesterol and incidence of ischaemic heart disease (IHD) events and stroke, according to drug, dose, and duration of treatment.

The effect of atorvastatin on serum lipids and lipoproteins in patients with …

The efficacy of atorvastatin, a new hydroxymethylglutaryl (HMG)-CoA reductase inhibitor, in reducing serum lipid levels, modifying lipoprotein composition, and suppressing cholesterol synthesis was evaluated in patients with homozygous familial hypercholesterolemia (homozygous FH) undergoing LDL-apheresis therapy. Atorvastatin was given in escalating doses (10, 20, and 40 mg:day) to nine patien…

CEFIXIME: A PHARMACOECONOMIC PERSPECTIVE

Cefixime, the first oral third-generation cephalosporin available, is commonly used for the treatment of upper and lower respiratory tract infections, otitis media, sinusitis, urinary tract infections, and gonorrhea. The drug has a number of characteristics that make it effective when administered once or twice daily: a half-life of 3 to 4 hours, activity against most common pathogens involved …

Double-Blind Study Comparing 3-Day Regimens of Cefixime and Ofloxacin in Trea…

This double-blind randomized study compared 3-day regimens of cefixime (400 mg once daily) and ofloxacin (200 mg twice a day) in the treatment of urinary tract infections in women. The respective clinical cure rates for the two groups of women were 89 and 92% after 7 days and 81 and 84% after 4 weeks. The respective microbiological cure rates (free of bacteriuria) for the two groups of women we…